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Abstract 
 
Background: To evaluate the efficacy of NS1 Antigen 
assay and Ig M in the diagnosis of dengue virus infection 
in its acute and early convalescent stages 
Methods: This prospective study was conducted in the 
Department of Medicine, DHQ Teaching Hospital 
Rawalpindi from 1st October 2010 to 10th November 2010. It 
included all 105 patients who presented with dengue fever 
during this period. Serum samples of all patients were sent 
for detection of NS1 Ag, Ig M and Ig G besides other 
routine investigations. The first four days of clinical 
illness were taken as the acute stage of the disease while 
the period from day 5 to day 10 was designated as the early 
convalescent stage. The efficacy of NS1 Ag and Ig M 
antibody in both stages was evaluated. 
Results: The 105 patients comprised of 74 males and 31 
females (male to female ratio 2.4:1). Age of patients ranged 
from 14 to 80 years. Mean age was 33.34 years. Thirty one 
patients presented in the acute stage of illness while 72 
were seen in the early convalescent stage. NS1 antigen was 
detected in 29 out of 31 patients presenting in the acute 
stage of dengue infection (93.55%) while Ig M was positive 
in 7 patients (22.58%). In the early convalescent stage, NS1 
antigen was detected in 12 of the 72 patients presenting in 
this period (16.6%). Ig M was positive in 64 out of 72 
patients (88.88%) in this stage. 
Conclusion: NS1 antigen assay is a very reliable test to 
diagnose dengue fever in the acute stage of illness. 
Detection of immunoglobulin M is a dependable test for 
diagnosis in the early convalescent period of the disease. 
Key Words: Dengue Fever, NS1 Antigen, 
Immunoglobulin M, Acute Stage, Early Convalescent 
Stage. 
 
Introduction 
 
Dengue fever (DF) is the most important 
arthropod-borne viral disease in terms of human 
morbidity and mortality. Each year over 100 million 
dengue infections occur leading to 500,000 
hospitalizations and an estimated 50,000 deaths1. 
According to World Health Organization (WHO) 
estimates, its incidence has increased by a factor of 30 
over the last 50 years2. It is now endemic in more than 
100 countries and poses a threat to more than 2.5 
billion people3, 4. No effective therapy exists. 
Dengue virus (DV) is transmitted to humans by 
Aedes aegypti (a.k.a. Stegomyia aegypti) mosquitoes. The 
clinical spectrum ranges from a self-limiting infection 
to more severe forms like “Dengue Haemorrhagic 
Fever” (DHF) or “Dengue Shock Syndrome” (DSS) 
where a mortality rate of up to 40% may be seen5. The 
viral genome is approximately 11 kilobases long and 
contains a single open reading frame encoding a 
polyprotein precursor of about 3400 amino acids. Co – 
and post transitional processing of the polyprotein by 
cellular and viral proteases gives rise to three 
structural proteins, designated C (core) protein, M 
(membrane) protein and E (envelope) protein as well 
as seven non-structural proteins, NS1, NS2a, NS2b, 
NS3, NS4a, NS4b and NS56-9. 
NS1 (non-structural protein 1) is a highly 
conserved glycoprotein that seems essential for the 
viability of dengue virus but has no established 
biological activity10. It is produced both in membrane-
associated and secretory forms by the virus. Enzyme-
linked immunosorbent assays (ELISA) directed against 
NS1 Antigen (NS1 Ag) have demonstrated its presence 
at high concentrations (1 to 10 mcg/ml) in the sera of 
dengue virus-infected patients during the early clinical 
phase of the disease10-14. Other diagnostic methods 
currently available include viral culture, viral RNA 
detection by “Reverse Transcriptase PCR” (RT-PCR) 
and serological tests such as “Immunoglobulin M (Ig 
M) capture enzyme-linked immunosorbent assay” 
(MAC-ELISA). The first two are either expensive or 
their routine use in clinical diagnostic facilities is 
difficult. MAC-ELISA kits are available for commercial 
use. However they cannot be used for early diagnosis 
because Ig M does not become detectable until 5 to 10 
days after the onset of illness in case of primary 
dengue infection and until 4 to 5 days after start of 
illness in secondary infections15. 
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Detection of secretory NS1 protein is a recent 
development and a new diagnostic tool for the 
diagnosis of acute DV infection. The purpose of this 
study was to evaluate the efficacy of NS1 Ag assay and 
Ig M in the diagnosis of dengue virus infection in its 
acute and early convalescent stages. 
 
Patients and Methods 
 
This prospective study was conducted in the 
Department of Medicine, DHQ Teaching Hospital 
Rawalpindi, a tertiary care referral centre of 
Rawalpindi Medical College. It included all 105 
patients presenting with dengue fever from 1st October 
2010 to 10th November 2010. All were aged over 14 
years and presented with an acute febrile illness. 
Dengue fever was suspected if two or more of the 
following features, in addition to fever were present: 
headache, retro-orbital pain, myalgias, arthralgias, 
scarlet/macular rash, vomiting/abdominal pain and 
haemorrhagic manifestations. Laboratory investigation 
criteria were also laid down. Patients with acute febrile 
illness having leucopenia (TLC < 4000/ cmm) and/or 
thrombocytopenia (platelets < 150000/ cmm) and 
deranged transaminases were also worked up for 
dengue fever. Blood samples for dengue virus Ig M 
were sent to National Institute of Health, Islamabad 
and our own hospital laboratory where the tests were 
performed by standardized ELISA method. 
 Samples for detection of NS1 Ag in sera were sent 
to a reliable laboratory offering this test. 
Immunochromatography method (ICT/Tan Bio 
Company) was employed. In this immunological 
assay, NS1 antigen present in the patient’s sample 
binds with colloidal gold complexes containing anti-
NS1 antibody. A procedural control is included to 
indicate that the assay has been performed correctly. 
Sensitivity and specificity of the assay is 80% and 95% 
respectively. A blood complete picture, liver function 
tests, serum urea and creatinine, prothrombin time 
and urine R/E were also obtained. Considering the 
overlapping signs and symptoms and endemic nature 
of typhoid and malaria, all patients also underwent 
appropriate smear or serological tests for these 
diseases (Typhidot and malarial parasite smears). 
Once a definite diagnosis of dengue fever was 
established, only symptomatic treatment was advised 
and the patient monitored for DHF and DSS using 
current guidelines of WHO and Pan American Health 
Organisation16. 
Dengue haemorrhagic fever was diagnosed when 
the patient fulfilled the following criteria: fever, any 
haemorrhagic manifestations and thrombocytopenia 
(platelet count 100,000/cmm or less). Objective 
evidence of increased capillary permeability, incipient 
and frank circulatory failure was taken to represent 
Dengue shock syndrome. 
The “Acute Stage” of dengue viral infection was 
defined as the period from day 1 to day 4 of the 
clinical illness while the period from day 5 to day 10 
was designated as the “Early Convalescent Stage”. The 
efficacy of NS1 Ag and Ig M antibodies in both the 
stages of dengue infection was evaluated. 
The clinical presentations and laboratory findings 
were recorded on a proforma especially designed for 
the purpose. Descriptive analysis was performed using 
SPSS v 10.0 programmer. 
 
Results 
 
The 105 patients studied comprised of 74 males 
and 31 females (male to female ratio 2.4:1). Age of 
patients ranged from 14 to 80 years. Mean age was 
33.34 years. The highest incidence occurred in those 
aged between 16 to 41 years, with 71 patients (68%) 
figuring in this age range. 
Thirty one patients presented in the acute stage of 
the illness while 72 were seen in the early convalescent 
stage. Two patients came on the 14th and 15th day of 
the clinical illness. Both were Ig M positive and NS1 
Ag negative for dengue fever. 
 
Table 1: NS1 Ag and Ig M antibody detection in 
the “Acute Stage” (n=31) 
Day Patients NS1 Ag 
Positive 
Ig M 
Positive 
One 2 2 (100%) - 
Two 5 4 (80%) 1 (20%) 
Three 11 11 (100%) - 
Four 13 12 (92.3%) 6 (46.2%) 
Total 31 29 7 
Positivity  93.55% 22.58% 
 
NS1 antigen was detected in 29 out of 31 (93.55%) 
patients presenting in the acute stage of dengue 
infection while Ig M was positive in 7 (22.58%) 
patients in this stage (Table 1). One patient who was Ig 
M positive on day 2 was also Ig G positive for dengue. 
In the early convalescent stage NS1 antigen was 
detected in 12 of the 72 (16.6%) patients presenting in 
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this period. Ig M was positive in 64 out of 72 (88.88%) 
patients in this stage (Table 2). 
Table 2: NS1 antigen and Ig M antibody 
detection in the “Early Convalescent Stage” (n=72) 
Day Patients NS1 Ag 
Positive 
Ig M 
Positive 
Five 21 10 (47.6%) 15 (71.4%) 
Six 14 0 14 (100%) 
Seven 24 2 (8.3%) 23 (95.8%) 
Eight 7 0 7 (100%) 
Nine - - - 
Ten 6 0 5 (83.3%) 
Total 72 12 64 
Positivity  16.6% 88.88% 
 
NS1 antigen detection registered a sharp fall on 
day 5 of the clinical illness when it was positive in 10 
out of 21 patients (46.7%). However Ig M positive 
patients quickly rose to 71.4% the same day reaching 
100% on day 6, being positive in all 14 patients tested 
on that day of illness (Table 2). 
Thirty five of our 105 patients developed clinical 
features of DHF. They were managed with platelet 
concentrates and blood transfusions. None developed 
signs of DSS. There was no mortality in this time 
period with all 105 patients recovering including those 
with DHF. 
Discussion 
  
This is not the first time that dengue fever has 
assumed epidemic proportions in Pakistan. The 
previous outbreak on a country-wide scale occurred in 
the last three months of 2006. During that period 220 
patients were managed by the present authors in 
Rawalpindi General Hospital (now Benazir Bhutto 
Hospital) Rawalpindi. These included 22 patients with 
DHF. All patients subsequently recovered17. 
 To limit disease expansion and bring down the 
significant mortality rate associated with DF, it is 
essential to have a rapid and sensitive laboratory test 
for early detection of the disease. NS1 Ag circulates 
uniformly in all serotypes of dengue virus and it 
circulates at high level during the first few days of 
illness18. Antigen levels as high as 2 to 10 mcg/ml may 
be found in acute stage sera14 while in the convalescent 
stage these may be 0.4 mcg/ml or less12. This is the 
likely explanation for the much higher detection rate 
of NS1 Ag in acute phase serum samples. It is possible 
that with production of specific immunoglobulins in 
the early convalescent stage, immune complexes are 
formed, resulting in low NS1 Ag positivity. 
 Our study demonstrated a high detection rate 
of NS1 Ag (93.55%) in the acute stage of illness. Rates 
above 90% have also been confirmed by other 
researchers10, 19. Datta et al11 noted a rapid decline in 
NS1 Ag positivity in the early convalescent stage with 
only 28.57% of their patients testing positive. This was 
even lower (16.6%) in our study. NS1 Ag may also be 
an indicator of disease severity18. In one study, very 
high levels, observed within 72 hours of illness, 
identified patients at risk of developing DHF14. A 
quantitative estimation of NS1 Ag was not carried out 
in this study. 
 Ig M positivity in excess of 90% in the early 
convalescent stage has been demonstrated by various 
authors10, 11, which is in conformity with our findings 
(88.9%). Ig M positivity in the acute phase of DF has 
been found to be as low as 6.38%11, whereas it was 
22.58% in our study. However, most of our Ig M 
positivity in the acute stage became evident on day 4 
of DF and most of these patients also tested positive 
for dengue Ig G. We infer that Ig M rises earlier in Ig G 
positive patients. 
 Day 5 of clinical disease seems to be important 
from a diagnostic view point since NS1 Ag serum 
levels start to fall whereas Ig M levels register a rise. 
Thus a negative NS1 Ag test at this juncture, coupled 
with a negative Ig M does not necessarily rule out DF. 
In such patients, we recommend that Ig M be tested 
again after 48 to 72 hours since antibody levels become 
detectable in most cases around this period. 
 The short time frame of our study impeded us 
from assembling any control group of consequence. 
However, seven patients with typhoid seen during this 
period did undergo dengue serological tests. Both Ig 
M and NS1 Ag were negative in all cases. Studies done 
on large control groups have established 100% 
specificity for both NS1 Ag and Ig M detection 
serological tests10, 11. Dengue serology is also negative 
in yellow fever, a disease to which it bears many a 
similarity10. 
 In conclusion, NS1 Ag assay is a very reliable 
test to diagnose DF in the acute stage of illness. 
Detection of immunoglobulin M is a dependable test 
in the early convalescent period. A diagnostic strategy 
combining NS1 Ag testing of serum samples collected 
within 5 days of the onset of fever and Ig M testing of 
serum samples obtained in the early convalescent 
stage seems to be the best policy to diagnose dengue 
fever in the vast majority of patients. 
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